Case todayNot read todayThesis-Break EngineThe case · holding · Nov 21, 2026Own ECX if it reverses recent gross-margin compression and converts improving operating leverage into positive cash flow before its negative equity forces dilutive financing.4 conditions2 strengthening · 2 holdingNext resultsNot scheduledNo date filed yet

ECX at a glance

The past year

Chart

−73.1% $0.50, close Nov 20

From the highest close
−76.4%
Vs the 200-day average
−55.6%
Nov 19, 2025Daily close, ECARX HoldingsNov 20, 2026

Short interest

History

7.3M shares

Since the last report
+21.3%
Days to cover
11 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

$318,287 bought on the open market

Purchases
1
Form 4s filed
Nov 16 – Nov 22

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

ECX price history

Latest price$0.53Today−$0.16 (-23.70%)
ECX -41.17%S&P 500 -10.82%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Revenue growth is being driven by expanding customer contracts and remains the primary engine for future margin and profit improvement.StrengtheningMateriality: High

    Annual revenue increased from $515,736,000 (2022) to $662,226,000 (2023) to $771,530,000 (2024) to $847,858,000 (2025) — sustained multi-year growth. If revenue growth continues, fixed R&D and SG&A can be absorbed and operating leverage can drive profitability; if growth stalls, the path to self-sufficiency vanishes and financing/dilution risk rises.

    Watch: Large customers (OEMs) could insource software or favor alternative suppliers/Tier-1s, reducing contract renewal rates or pricing.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Annual revenue increased from $515,736,000 (2022) to $662,226,000 (2023) to $771,530,000 (2024) to $847,858,000 (2025) — sustained multi-year growth.

    Open source ↗
  • Operating losses are materially narrowing due to operating leverage (scale) and/or expense control, creating a plausible path to operating profitability if revenue growth continues.StrengtheningMateriality: High

    Operating income improved from -$212,591,000 (2022) to -$130,016,000 (2023) to -$122,896,000 (2024) to -$54,773,000 (2025). Sustained improvement in operating income would validate the business model converting scale into profits and reduce dependence on financing.

    Watch: If management increases R&D or goes after low-margin hardware opportunities, expense creep could erase operating-leverage gains.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Operating income improved from -$212,591,000 (2022) to -$130,016,000 (2023) to -$122,896,000 (2024) to -$54,773,000 (2025).

    Open source ↗
  • Gross-margin compression (product mix or pricing) has been a material headwind; reversing or stabilizing gross margin is necessary for durable profitability.HoldingMateriality: Medium

    Gross profit was $143,609,000 (2022), $178,618,000 (2023), $160,099,000 (2024) and $161,262,000 (2025) while revenue grew — implying gross margin fell materially (percentage decline evident from these levels). Even with operating leverage, persistent low gross margins restrict ultimate operating margin ceiling and make profitability fragile; continuing compression would require unrealistically large SG&A cuts to reach break-even.

    Watch: If the company shifts sales mix toward higher-margin software/services or renegotiates pricing with OEMs, margins could recover.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Gross profit was $143,609,000 (2022), $178,618,000 (2023), $160,099,000 (2024) and $161,262,000 (2025) while revenue grew — implying gross margin fell.

    Open source ↗
  • The company remains dependent on external financing until operating cash flow turns positive; cash recovery in 2025 likely reflects financing activity rather than sustained internal cash generation.HoldingMateriality: Medium

    Cash and cash equivalents: $106,911,000 (2022) → $80,283,000 (2023) → $44,250,000 (2024) → $87,118,000 (2025) (rebound in 2025). If operating cash flow does not turn positive, ECARX will need to raise capital, causing dilution or covenant pressure given negative equity and high liabilities.

    Watch: If upcoming quarters show sustained positive operating cash flow, the financing reliance dissipates.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash and cash equivalents: $106,911,000 (2022) → $80,283,000 (2023) → $44,250,000 (2024) → $87,118,000 (2025) (rebound in 2025).

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Revenue growth is being driven by expanding customer contracts and remains the primary engine for future margin and profit improvement. If revenue growth continues, fixed R&D and SG&A can be absorbed and operating leverage can drive profitability; if growth stalls, the path to self-sufficiency vanishes and financing/dilution risk rises.

Operating losses are materially narrowing due to operating leverage (scale) and/or expense control, creating a plausible path to operating profitability if revenue growth continues. Sustained improvement in operating income would validate the business model converting scale into profits and reduce dependence on financing.

Gross-margin compression (product mix or pricing) has been a material headwind; reversing or stabilizing gross margin is necessary for durable profitability. Even with operating leverage, persistent low gross margins restrict ultimate operating margin ceiling and make profitability fragile; continuing compression would require unrealistically large SG&A cuts to reach break-even.

The company remains dependent on external financing until operating cash flow turns positive; cash recovery in 2025 likely reflects financing activity rather than sustained internal cash generation. If operating cash flow does not turn positive, ECARX will need to raise capital, causing dilution or covenant pressure given negative equity and high liabilities.

All standing thesis claims
Original report summary

it reverses recent gross-margin compression and converts improving operating leverage into positive cash flow before its negative equity forces dilutive financing.

Evidence assessed Nov 21, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for ECARX Holdings

Where the evidence on ECARX Holdings stands: Holding on the latest evidence (Nov 21, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.

Bull case: what the evidence supports

  • Revenue growth is being driven by expanding customer contracts and remains the primary engine for future margin and profit improvement.

    sec.gov ↗

  • Operating losses are materially narrowing due to operating leverage (scale) and/or expense control, creating a plausible path to operating profitability if revenue growth continues.

    sec.gov ↗

  • Gross-margin compression (product mix or pricing) has been a material headwind; reversing or stabilizing gross margin is necessary for durable profitability.

    sec.gov ↗

  • The company remains dependent on external financing until operating cash flow turns positive; cash recovery in 2025 likely reflects financing activity rather than sustained internal cash generation.

    sec.gov ↗

Bear case: what would count against it

  • Large customers (OEMs) could insource software or favor alternative suppliers/Tier-1s, reducing contract renewal rates or pricing.

    sec.gov ↗

  • If management increases R&D or goes after low-margin hardware opportunities, expense creep could erase operating-leverage gains.

    sec.gov ↗

  • If the company shifts sales mix toward higher-margin software/services or renegotiates pricing with OEMs, margins could recover.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · ECARX Holdings

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed ECARX Holdings’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Foreign issuer material report (6-K).

    ECARX Holdings filed an SEC report on 2026-11-04: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  2. Mixed
    Foreign issuer material report (6-K).

    ECARX Holdings filed an SEC report on 2026-11-02: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  3. Mixed
    Foreign issuer material report (6-K).

    ECARX Holdings filed an SEC report on 2026-10-30: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Large customers (OEMs) could insource software or favor alternative suppliers/Tier-1s, reducing contract renewal rates or pricing.
  • If management increases R&D or goes after low-margin hardware opportunities, expense creep could erase operating-leverage gains.
  • If the company shifts sales mix toward higher-margin software/services or renegotiates pricing with OEMs, margins could recover.
  • If upcoming quarters show sustained positive operating cash flow, the financing reliance dissipates.

ECX news

Loading headlines…

Financial statements

ECX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ECX: quick answers

What is ECX's short interest?
As of October 30, 2026, 7.3M ECX shares were sold short, up 21.3% from the count before. At the stock's average daily volume that is 11 days to cover. FINRA publishes the count twice a month. ECX short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.